Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic Abnormality

NCT04668365 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT04668365
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04668365 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm, Multi-center, Phase II Clinical Trial of Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma and CD79A/CD79B Genetic Abnormality
Lead sponsor
Henan Cancer Hospital
Phase
Phase 2
Overall status
Suspended
Start date
December 25, 2020
Completion date
December 25, 2025
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cd79a gene mutation, cd79b gene mutation, diffuse large b cell lymphoma